Diagnosis of Granulocytic Ehrlichiosis in Humans by Immunofluorescence Assay

P. BROUQUI,1* E. SALVO,1 J. S. DUMLER,2 AND D. RAOULT1

Unité des rickettsies, WHO Collaborative Center for Rickettsial Reference and Research, CNRS UPRES A 6020, Faculté de Médecine, 13385 Marseille Cedex 5 France, 1 and Division of Medical Microbiology, Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland2

Received 19 July 2000/Returned for modification 16 August 2000/Accepted 10 October 2000

Serodiagnostic tests are widely available for tick-borne diseases. We evaluated a cell-free antigen of the human granulocytic ehrlichiosis agent. Immunofluorescence assay (IFA) with this antigen is as efficient as with the MRL kit and allows a one-step IFA with other cell-free antigens that is useful when testing sera from patients bitten by ticks.

Human granulocytic ehrlichiosis (HGE) is caused by an obligate intracellular bacterium closely related to Ehrlichia phagocytophila (9). The bacteria are transmitted by Ixodes ticks (6) and share these vectors with Borrelia burgdorferi and Babesia microti in the United States and with B. burgdorferi, Babesia canis, Rickettsia helvetica, and the tick-borne encephalitis virus group in Europe (4).

Serology is currently the most widely available diagnostic laboratory test (5, 12, 15). These tests use intracellular antigens fixed onto slides and preserved at −80°C or are packed in light-protected paper. In our laboratory we systematically screen sera referred to us from patients bitten by ticks with a single test that includes several cell-free rickettsial antigens such as Rickettsia conori, R. helvetica, R. massiliae, R. slovaca, R. africae, Bartonella quintana, Bartonella henselae, and Francisella tularensis. We compared immunofluorescence assay (IFA) with cell-free antigen of the HGE agent to the intracellular antigen from the same strain and to a commercially available IFA test (MRL Diagnostic, Cypress, Calif.).

The Webster strain of the HGE agent was propagated in HL-60 cells (ATCC CL240) (8). Intracellular ehrlichiae in HL-60 cells were preloaded onto slides, fixed with acetone, and stored at −80°C. A kit using the same type of preparation but with another HGE agent isolate and packed in light-protected paper was also tested (MRL kit). Our cell-free purified antigen was obtained by differential centrifugation of 100% infected HL-60 cells and stored at −80°C. Positive-control antibodies were prepared in rabbits. For the MRL kit, immunoglobulin G (IgG) and IgM were tested separately at a screening dilution of 1:32 for IgG and 1:20 for IgM. For the other antigens, three dilutions (1:16, 1:32, 1:64) of sera were used. When the serum titer was greater than 1:32, it was retested for IgG and IgM separately. Separate individuals reviewed stained slides twice blindly. When discrepant results were observed, the test was repeated.

A case was defined by the Centers for Disease Control and Prevention surveillance definition for human ehrlichiosis (5). Noncases were defined as either asymptomatic unexposed blood donors or acutely ill patients with a different proven etiologic diagnosis.

In order to evaluate the different tests we compared the predictive values of each in relationship to the expected prevalence of the disease. For that we use Bayes’ theorem: positive predictive value (PPV) = SE × PR/(SE × PR) + (1 − SP) × (1 − PR), and negative predictive value (NPV) = SPE × (1 − PR)/SPE × (1 − PR) + (1 − SE) × PR, where PR is the prevalence of the disease in the concerned population, SPE is specificity, and SE is sensitivity. PR of ehrlichiosis varies from 2.5 to 5.8 cases per 10,000 members of the population (3, 11).

Graphs and statistical analysis were obtained using Microsoft Excel 7 and Epi info 6.0.

We tested 30 sera from case patients and 137 sera from noncase patients. The SEN of the test was significantly greater with the MRL antigen than the intracellular (IC) antigen (P = 0.0098233 and P = 0.0099243) (Table 1).

Serological cross-reactions occurred mostly with IgG in patients with endocarditis (Table 2). At least 6 of 10 sera from patients with Bartonella spp. endocarditis cross-reacted with all Ehrlichia antigens tested. In most cases IgG titers were elevated. The PPV as well as the NPV at an IgG cutoff of >32 were comparable between MRL and purified antigen (PA) and better than with IC antigen, whatever the PR of the disease (Fig. 1A and B). The PPV was better with both PA and IC antigens at an IgM cutoff of >32 than by the MRL test at an IgM cutoff of >20 (Fig. 1C). However, the predictive value of a negative IgM test was similar for the three antigen preparations (Fig. 1D).

The SEN of tests using different strains of intracellular antigen varied between 60 and 100%, although the differences were not statistically significant (15). We found the MRL test for IgG and IgM or IgG alone to be more sensitive than IFA with intracellular HGE agent Webster strain (P = 0.009). The MRL IFA test uses a human-derived isolate of the HGE agent (HGE1 strain) obtained from J. L. Goodman (Department of Medicine, University of Minnesota Academic Health Center) that is genetically very close to the human Webster strain. The discovery that isolates of the HGE agent and Ehrlichia equi are antigenically diverse suggests that differences in SE and SPE...
TABLE 1. SEN and SPE of IFA using different sources of granulocytic ehrlichial antigen

| Antigen source | Antibody tested and cutoff titer | No. of: | SEN | No. of: | SPE |
|----------------|----------------------------------|---------|-----|---------|-----|
|                | TP | FN | TN | BD | MSF | AOF | BE | EBV | CMV | COF | SLE | Total |
| PA             |    |    |    |    |    |    |    |    |    |    |    |        |
| IgG or IgM > 32 | 25 | 5  | 0.833 | 127 | 2 | 1 | 0 | 7 | 0 | 0 | 0 | 10 | 0.927 |
| IgG > 32       | 24 | 6  | 0.800 | 127 | 2 | 1 | 0 | 7 | 0 | 0 | 0 | 10 | 0.927 |
| IgG > 16       | 25 | 5  | 0.833 | 121 | 8 | 1 | 0 | 7 | 0 | 0 | 0 | 16 | 0.883 |
| IgG > 8        | 25 | 5  | 0.833 | 120 | 9 | 1 | 0 | 7 | 0 | 0 | 0 | 17 | 0.875 |
| IgM > 32       | 8  | 22 | 0.266 | 137 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.666 |
| IgM > 16       | 12 | 18 | 0.400 | 129 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 0.941 |
| IgM > 8        | 19 | 11 | 0.633 | 117 | 20 | 0 | 0 | 0 | 0 | 0 | 0 | 20 | 0.854 |
| IC             |    |    |    |    |    |    |    |    |    |    |    |        |
| IgG or IgM > 32 | 20 | 10 | 0.666** | 124 | 3 | 0 | 0 | 6 | 0 | 1 | 2 | 13 | 0.905 |
| IgG > 32       | 17 | 13 | 0.566* | 124 | 3 | 0 | 0 | 6 | 0 | 1 | 2 | 13 | 0.905 |
| IgG > 16       | 23 | 7  | 0.766 | 121 | 6 | 0 | 0 | 6 | 0 | 1 | 2 | 16 | 0.883 |
| IgG > 8        | 23 | 7  | 0.766 | 117 | 10 | 0 | 0 | 6 | 0 | 1 | 2 | 20 | 0.854 |
| IgM > 32       | 11 | 19 | 0.366 | 136 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0.992 |
| IgM > 16       | 17 | 13 | 0.566 | 131 | 5 | 0 | 0 | 1 | 0 | 0 | 0 | 6 | 0.956 |
| IgM > 8        | 20 | 10 | 0.666 | 121 | 15 | 0 | 0 | 1 | 0 | 0 | 0 | 16 | 0.883 |
| MRL            |    |    |    |    |    |    |    |    |    |    |    |        |
| IgG > 32 or IgM > 20 | 28 | 2  | 0.933** | 126 | 2 | 1 | 1 | 7 | 0 | 0 | 0 | 11 | 0.919 |
| IgG > 32       | 26 | 4  | 0.866* | 127 | 1 | 1 | 1 | 7 | 0 | 0 | 0 | 10 | 0.927 |
| IgG > 16       | 27 | 3  | 0.900 | 123 | 5 | 1 | 1 | 7 | 0 | 0 | 0 | 14 | 0.897 |
| IgG > 8        | 27 | 3  | 0.900 | 116 | 12 | 1 | 1 | 7 | 0 | 0 | 0 | 21 | 0.846 |
| IgM > 20       | 10 | 20 | 0.333  | 135 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0.985 |

* Sera used were from 30 proven HGE cases and 137 control sera from Blood Donors (BD) (n = 96), Mediterranean (MSF) spotted fever (n = 10), Bartonella endocarditis (BE) (n = 10), Epstein-Barr virus (EBV) (n = 2), cytomegalovirus (CMV) (n = 3), (CQF) Chronic Q fever (n = 3), and systemic lupus erythematosus (SLE) (n = 3). Symbols: *, Difference is significant with P = 0.0098233 (chi-square test); **, Difference is significant with P = 0.0099243 (chi-square test). Abbreviations: TP, true positive; TN, true negative; FP, false positive; FN, false negative.

may exist (1, 2, 10, 13). Serological cross-reactions occurred mostly with Bartonella endocarditis. Endocarditis is often characterized by very high specific antibody titers and by frequent lower-titer serological cross-reactions (4a).

Whatever the PR of the disease both PA and MRL tests have good PPVs and NPVs. The comparatively lower predictive value of an IgM-positive test with MRL antigens is likely due to the fact that the cutoff used is lower than that with other antigens, leading to lower SPE. The good predictive value of a negative test with all of the antigens and regardless whether tested for IgG or IgM indicates that a negative result in our population is unlikely to occur in a case patient.

Unlike cells infected with monocytic ehrlichiae, granulocytic ehrlichiae grown in immature HL-60 cells clumped together when frozen and thawed. Consequently, antigen slides for serological diagnosis of granulocytic ehrlichiosis are prepared with freshly infected cells, fixed, and preserved as antigen slides either frozen or in light-protected paper (7, 12, 15). Micro immunofluorescence diagnosis of other intracellular rickettsial infections can be made with cell-free antigens (14). IFA testing

TABLE 2. Serological cross-reaction with serum from patients with other documented diseases

| Antigen source | Population tested (n)* | No. of specimens IgG positive/total no. tested | IgG titer(s) | No. of specimens IgM positive/total no. tested | IgM titer |
|----------------|------------------------|-----------------------------------------------|--------------|-----------------------------------------------|-----------|
| PA             |                        |                                               |              |                                               |           |
| Acute MSF (10) | 1/10                   | 64                                            |              |                                               |           |
| Acute Q fever (10) | 0                    | <32                                           |              |                                               |           |
| Acute CMV infection (3) | 0                  | <32                                           |              |                                               |           |
| Bartonella sp. endocarditis (10) | 7/10                | 2,048, 1,024, 8,192, 256, 128, 512, 1,024 |              |                                               |           |
| Q fever endocarditis (3) | 0                   | <32                                           |              |                                               |           |
| Systemic lupus erythematosus (3) | 0                | <32                                           |              |                                               |           |
| IC             |                        |                                               |              |                                               |           |
| Acute MSF (10) | 0                      | <32                                           |              |                                               |           |
| Acute Q fever (10) | 0                    | <32                                           |              |                                               |           |
| Acute CMV infection (3) | 1/3                 | 64                                            |              |                                               |           |
| Bartonella sp. endocarditis (10) | 6/10                | 1,024, 1,024, 4,096, 128, 64, 128              |              |                                               |           |
| Q fever endocarditis (3) | 0                   | 256, 512                                      |              |                                               |           |
| Systemic lupus erythematosus (3) | 1/3                | 64                                            |              |                                               |           |
| MRL            |                        |                                               |              |                                               |           |
| Acute MSF (10) | 1/10                   | 128                                           |              |                                               |           |
| Acute Q fever (10) | 1/10                  | 256                                           |              |                                               |           |
| Acute CMV infection (3) | 0                 | <32                                           |              |                                               |           |
| Bartonella sp. endocarditis (10) | 7/10                | 512, 512, 2,048, 64, 256, 128, 256            |              |                                               |           |
| Q fever endocarditis (3) | 0                   | <32                                           |              |                                               |           |
| Systemic lupus erythematosus (3) | 0                | <32                                           |              |                                               |           |

* MSF, Mediterranean spotted fever; CMV, cytomegalovirus.
FIG. 1. PPVs (A and C) and NPVs (B and D) of HGE screening using IgG (A and B) and IgM (C and D).

Negative predictive value of IgM > 22 (D and E) related to prevalence of the disease.

Positive predictive value of IgG > 22 related to prevalence of the disease.
with cell-free antigens is as efficient and predictive as commercially prepared serologic kits, storage is easier, and it allows performance of a one-step IFA using several cell-free antigens of interest when testing sera from patients with tick bites. Elevated IgG titers in a patient with a clinical and epidemiological history not compatible with ehrlichiosis might suggest *Bartonella* endocarditis.

We thank Jane Markley from MRL laboratory for her support with the *Ehrlichia* IFA diagnostic kits, and Johan Bakken for assistance with identifying patients.

**REFERENCES**

1. Aguero-Rosenfeld, M. E., F. Kalantarpour, M. Baluch, H. W. Horowitz, D. F. McKenna, J. T. Raffal, T. Hsieh, J. Wu, J. S. Dumler, and G. P. Wormser. 2000. Serology of culture-confirmed cases of human granulocytic ehrlichiosis. J. Clin. Microbiol. 38:635–638.
2. Asanovich, K. M., J. S. Bakken, J. E. Madigan, M. Aguero-Rosenfeld, G. P. Wormser, and J. S. Dumler. 1997. Antigenic diversity of granulocytic Ehrlichia isolates from humans in Wisconsin and New York and a horse in California. J. Infect. Dis. 176:1029–1034.
3. Bakken, J. S., J. Krueth, C. Wilson-Nordskog, R. L. Tilden, K. Asanovich, and J. S. Dumler. 1996. Clinical and laboratory characteristics of human granulocytic ehrlichiosis. JAMA 275:199–205.
4. Brouqui, P. 1999. Ehrlichiosis in Europe, p. 220–232. In D. Raoult and P. Brouqui. (ed.), Rickettsiae and Rickettsial diseases at the turn of the third millennium. Elsevier, Paris, France.
5. Comer, J. A., W. L. Nicholson, J. G. Olson, and J. E. Childs. 1999. Serologic testing for human granulocytic ehrlichiosis at a national referral center. J. Clin. Microbiol. 37:558–564.
6. Dumler, J. S., and J. S. Bakken. 1998. Human ehrlichioses: newly recognized infections transmitted by ticks. Annu. Rev. Med. 49:201–213.
7. Fingerle, V., J. L. Goodman, R. C. Johnson, T. J. Kurtti, U. G. Munderloh, and B. Wilke. 1997. Human granulocytic ehrlichiosis in southern Germany: increased seroprevalence in high-risk groups. J. Clin. Microbiol. 35:3244–3247.
8. Goodman, J. L., C. Nelson, B. Vitale, J. E. Madigan, J. S. Dumler, T. J. Kurtti, and U. G. Munderloh. 1996. Direct cultivation of the causative agent of human granulocytic ehrlichiosis. N. Engl. J. Med. 334:209–215. (Erratum, 335:361, 1996.)
9. Macleod, J. 1932. Preliminary studies in the tick transmission of loupin ill.II: a study of the reacation of sheep to tick infestation. Vet. J. 88:276–284.
10. Magnarelli, L. A., J. W. Ljubo, J. S. Dumler, R. Heimer, and E. Fikrig. 1998. Reactivity of human sera to different strains of granulocytic ehrlichiae in immunodiagnostic assays. J. Infect. Dis. 178:1835–1838.
11. McQuiston, J. H., C. D. Paddock, R. C. Holman, and J. E. Childs. 1999. The human ehrlichioses in the United States. Emerg. Infect. Dis. 5:635–642.
12. Nicholson, W. L., J. A. Comer, J. W. Summer, C. Gingrich-Baker, R. T. Coughlin, L. A. Magnarelli, J. G. Olson, and J. E. Childs. 1997. An indirect immunofluorescence assay using a cell culture-derived antigen for detection of antibodies to the agent of human granulocytic ehrlichiosis. J. Clin. Microbiol. 35:1510–1516.
13. Petrovec, M., F. S. Lotric, T. A. Zapanc, F. Strle, P. Brouqui, V. Roux, and J. S. Dumler. 1997. Human disease in Europe caused by a granulocytic Ehrlichia species. J. Clin. Microbiol. 35:1556–1559.
14. Tissot-Dupont, H., P. Brouqui, B. Faugere, and D. Raoult. 1995. Prevalence of antibodies to Coxiella burnetti, Rickettsia conorii, and Rickettsia typhi in seven African countries. Clin. Infect. Dis. 21:1126–1133.
15. Walls, J. J., M. Aguero-Rosenfeld, J. S. Bakken, J. L. Goodman, D. Hossain, R. C. Johnson, and J. S. Dumler. 1999. Inter- and intralaboratory comparison of *Ehrlichia* equi and human granulocytic ehrlichiosis (HGE) agent strains for serodiagnosis of HGE by the immunofluorescent-antibody test. J. Clin. Microbiol. 37:2968–2973.